

Supplemental Table 2. Cohort and clinicopathological data for metastasis cores.

	Non-responders	Responders
Sex		
Female	4 (50.0%)	6 (75.0%)
Male	4 (50.0%)	2 (25.0%)
Age (\pm SD)	65.1 \pm 6.4	67.5 \pm 4.8
Smoking Status		
Smoker	7 (87.5%)	8 (100.0%)
Non-smoker	1 (12.5%)	0 (0%)
Histology		
Adenocarcinoma	6 (75.0%)	7 (87.5%)
Squamous	1 (12.5%)	1 (12.5%)
Other	1 (12.5%)	0 (0%)
Stage at diagnosis		
IA2	0 (0%)	1 (12.5%)
IB	3 (37.5%)	1 (12.5%)
IIA	0 (0%)	2 (25.0%)
IIB	1 (12.5%)	1 (12.5%)
IIIA	3 (37.5%)	2 (25.0%)
IIIB	1 (12.5%)	0 (0%)
IVA	0 (0%)	1 (12.5%)
Specimen		
Biopsy	5 (62.5%)	1 (12.5%)
Surgical resection	0 (0%)	2 (25.0%)
Cytology	3 (37.5%)	5 (62.5%)
Site		
Distant Metastasis	5 (62.5%)	3 (37.5%)
Lymph Node	2 (25.0%)	4 (50.0%)
Pleural Effusion	1 (12.5%)	1 (12.5%)
Radiation		
Yes	2 (25.0%)	3 (37.5%)
No	6 (75.0%)	5 (62.5%)
Chemotherapy		
Yes	6 (75.0%)	3 (37.5%)
No	2 (25.0%)	5 (62.5%)
Immunotherapy		
Atezolizumab	0 (0%)	1 (12.5%)
Nivolumab	2 (25.0%)	1 (12.5%)
Pembrolizumab	6 (75.0%)	6 (75.0%)
Progression-free survival (\pm SD)	36.2 months \pm 27.5 months	90.2 months \pm 48.9 months
Overall survival (\pm SD)	41.1 months \pm 26.0 months	95.3 months \pm 46.3 months